What did @pharmagain_my actually say?
This video is an introduction reel for Dr. Ben, the new medical consultant for Pharmagain, a peptide retailer. He describes himself as a medical doctor who specializes in men's health, hormone optimization, and physical performance. He says he has coached "more than 1000 athletes" using "PEDs and peptides" and that he personally uses Pharmagain products, tracking his own response through blood tests. His closing line: Pharmagain is "the one and only peptide that's doctor proven and champion approved."
The video frames itself as educational, but it is, plainly, a brand endorsement. There is no disclosure of a paid or consulting relationship in the visible caption, which is a red flag on a regulated health platform. The claims made are a mix of reasonable safety messaging, some genuine nuance about quality control, and at least one marketing claim that has no scientific meaning.
Does the science back this up?
On peptide quality, he is largely correct. The evidence that peptide purity matters is not disputed. Poorly manufactured peptides can contain endotoxins, incorrect amino acid sequences, or degradation products. Independent third-party testing is genuinely important, and the research community has flagged this consistently.
But here is the problem: self-monitoring through "blood tests, tracked recovery, energy, sleep" is not clinical evidence. That is anecdote. The peptides he references under Pharmagain's umbrella, including BPC-157, TB-500, CJC-1295, and ipamorelin, have limited human clinical trial data. BPC-157 has promising animal data, including Sikiric et al. (2018, Current Pharmaceutical Design), but no completed randomized controlled trials in humans as of 2024. TB-500 (thymosin beta-4) similarly lacks human RCT data. CJC-1295 has small human studies, including Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism), showing GH pulse augmentation, but long-term safety data is thin. Claiming these are simply "tools" that produce "stable, consistent and predictable" results oversimplifies a genuinely uncertain evidence base.
What did they get wrong (or right)?
Credit where it is due: the emphasis on tested, dosed, and quality-controlled products is correct and responsible. The peptide grey market is full of underdosed or contaminated products, and a consultant pushing back on "anonymous labs" is saying the right thing.
However, several things fall apart under scrutiny. First, the phrase "doctor proven" is not a scientific or regulatory category. It is a marketing phrase, and attaching a medical title to it does not make it meaningful. Second, his framing of PED and peptide use as something done "correctly and safely" under medical guidance is complicated by the fact that most of these compounds are not approved by health regulators in Malaysia or most jurisdictions for the uses described. That is not a minor footnote. Third, running a supplement brand while serving as medical consultant for a peptide company creates a clear conflict of interest that is not disclosed or addressed in the video. That matters when you are presenting yourself as an objective clinical voice.
What should you actually know?
Peptides sold for recovery, anti-aging, and performance are largely operating outside standard drug approval frameworks. In Malaysia, compounds like BPC-157 and TB-500 are not registered therapeutic products under the National Pharmaceutical Regulatory Agency. That does not automatically make them dangerous, but it does mean there is no regulatory backstop on dosing, purity standards, or adverse event reporting at the consumer level.
Third-party lab testing, which Pharmagain claims to provide, is genuinely useful, but testing for purity does not equal testing for safety or efficacy in humans. A peptide can be 99% pure and still have no proven human benefit for the claimed use. The science is early, the regulatory status is murky, and anyone presenting these compounds as reliable clinical tools should be upfront about those limitations. A consultant who does not mention them is doing their audience a disservice, regardless of credentials.
- Ask any peptide brand for certificates of analysis from independent, accredited labs, not in-house testing.
- Be skeptical of personal anecdote, including from doctors, as a substitute for clinical trial data.
- Check whether the prescribing or recommending practitioner has disclosed all commercial relationships.
- Understand that "used by athletes" is not evidence of safety or efficacy for general populations.